| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Papapetropoulos Spyros serves as a Director at LPCN. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $10K at current prices.
The biggest single holding is LPCN (~$10K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 21,739 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2022 | LPCN Lipocine Inc. | Director | Buy | 21,739 | $0.47 | $10,217.33 | New | +5.7% | -68.4% |